Q2 2024 Ligand Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Ligand Pharmaceuticals Inc (LGND) reported a 58% increase in total revenue for the second quarter, driven by milestone payments from recent product approvals.
- The company's royalty revenue grew by 11% over the same period in 2023, indicating a strong growth trajectory.
- Ligand Pharmaceuticals Inc (LGND) expanded its royalty portfolio to include 12 major commercial stage products, doubling the number from the beginning of 2023.
- The acquisition of Apeiron Biologics is expected to be highly accretive, adding $1 per share on an annualized basis.
- The company has a strong cash position with $230 million in cash and investments, and an additional $125 million available under a credit facility with Citibank.
- Ligand Pharmaceuticals Inc (LGND) reported a GAAP net loss of $51.9 million for the second quarter, primarily due to reductions in the carrying value of certain investments.
- The departure of President and COO Matt Korenberg may lead to transitional challenges within the company's leadership team.
- The company incurred a $26.5 million financial royalty impairment related to Takeda's Soticlestat due to disappointing Phase 3 results.
- Increased G&A expenses by $6.3 million, driven by investments in the Pelthos business and expansion of the business development team.
- The company's investment in Primrose Bio saw a decrease in value, contributing to a $32 million other expense in the quarter.
Thank you for standing by. My name is Pam, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligand second quarter 2024 earnings webcast. (Operator Instructions)
I would now like to turn the conference over to Tavo Espinoza, the Chief Financial Officer of Ligand Pharmaceuticals Inc. You may begin.
Good afternoon, everyone, and welcome to Ligand's second quarter earnings call. During the call today, we will review the financial results, we released after today's market close and offer commentary on our partner -- pipeline and business development activities, followed by a question and answer session.
Our earnings release and a link to today's webcast can be found in the Investor Relations section of our website at ligand.com. With me on the call today are CEO, Todd Davis; Senior Vice President of Investments and business development, Paul Hadden; and Senior Vice President of Investment and Head of Clinical Strategy. Dr.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
